Actively Recruiting
Neuroprotective Effect of (Nano PSO), in Patients Who Used to Consume Psychoactive Substances
Led by Distribuidora Biolife SA de CV · Updated on 2024-08-12
80
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Addiction problems to psychoactive substances are becoming more frequent, which implies a serious health problem, with social, family and work repercussions. Participants with chronic consumption present important degeneration processes mediated by Neuroinflammation, oxidative stress and excitotoxicity. At the moment there is no effective treatment that can reduce the damage. The effectiveness of Omega 5 has been demonstrated in different disorders of the nervous system; However, very little has been elucidated about the mechanisms of regulation and activation in consumer patients. Omega 5 Nano-PSO has an important role in mechanisms of cell survival in different pathological events. In this project aims to explain the possible mechanisms underlying the morphological changes and pathologies associated with oxidative stress and inflammation, since it could be a useful strategy to counteract the effects of substances of abuse on brain cells. Omega 5 (Nano PSO) will modify the levels of neurotrophic factors through the decrease in inflammation and reactive oxygen species in patient-consumers of substances, reducing neuronal death and therefore cognitive deterioration. Methodological design Type of study: Clinical trial, randomized controlled, double blind. Research Headquarters: This work will be carried out at the University Center for Health Science with the participation of the "My family is waiting for me" rehabilitation centers. Study Period: 2 years
CONDITIONS
Official Title
Neuroprotective Effect of (Nano PSO), in Patients Who Used to Consume Psychoactive Substances
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male patients aged 18 to 50 years
- History of at least 3 years of multiple use of methamphetamines, cocaine, and cannabis, with or without alcohol and tobacco
- Currently in the withdrawal phase and residential treatment
- Acceptance and signing of informed consent to participate
You will not qualify if you...
- Individuals younger than 18 years
- Patients who do not sign the informed consent
- Patients discharged before the 6-month study period, requested by family
- Patients with known or developed allergies
- Patients currently using NSAIDs, MAOIs, or with active chronic inflammatory diseases or any type of cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Irene Guadalupe Aguilar García PhD.
Guadalajara, Jalisco, Mexico
Actively Recruiting
Research Team
I
Irene G Aguilar, PH
CONTACT
R
Rolando Castañeda, PH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here